PBLS

Parabilis Medicines Inc

Jun 15 • 04:00PM ET

25.01

-2.25 -8.25 %

Healthcare • Biotechnology • USA • Micro • NASD

Index	-	P/E	-	EPS (ttm)	-	Insider Own	-	Shs Outstand	3.27M	Perf Week	-
Market Cap	81.78M	Forward P/E	-	EPS next Y	-	Insider Trans	-	Shs Float	-	Perf Month	-
Enterprise Value	620.43M	PEG	-	EPS next Q	-	Inst Own	-	Short Float	-	Perf Quarter	-
Income	-	P/S	-	EPS this Y	-	Inst Trans	-	Short Ratio	-	Perf Half Y	-
Sales	-	P/B	-	EPS next Y	-	ROA	-	Short Interest	-	Perf YTD	-20.85%
Book/sh	-4.83	P/C	0.25	EPS next 5Y	-	ROE	-	52W High	34.47 -27.45%	Perf Year	-
Cash/sh	100.62	P/FCF	-	EPS past 3/5Y	- -	ROIC	-	52W Low	26.61 -6.01%	Perf 3Y	-
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	- -	Perf 5Y	-
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	-	Oper. Margin	-	ATR (14)	5.35	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	6.12	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	-	Recom	-
Dividend Gr. 3/5Y	- -	Current Ratio	6.12	EPS Q/Q	-	SMA20	-12.38%	Beta	-	Target Price	-
Payout	-	Debt/Eq	0.22	Sales Q/Q	-	SMA50	-12.38%	Rel Volume	0.47	Prev Close	27.26
Employees	-	LT Debt/Eq	0.15	Earnings	-	SMA200	-12.38%	Avg Volume	2.71M	Price	25.01
IPO	Jun 10, 2026	Option/Short	No / Yes	EPS/Sales Surpr.	- -	Trades		Volume	1,280,154	Change	-8.25%

Jun-11-26 04:05PM	Parabilis Medicines Announces Closing of Upsized Initial Public Offering, Including Full Exercise of Underwriters' Option to Purchase Additional Shares (GlobeNewswire) -10.06%
Jun-09-26 08:22PM	Parabilis Medicines Announces Pricing of Upsized Initial Public Offering (GlobeNewswire)

Fog Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company. It discovers and develops cell-penetrating miniproteins (CPMPs), which are specifically designed to target cancer-causing proteins inside cancer cells and neutralize them. The company was founded by Gregory L. Verdine, WeiQing Zhou and David Philip Lane in 2015 and is headquartered in Cambridge, MA.

Ph.D.Dr. Mathai Mammen M.D.

Executive VPMs. Teresa L. Jurgensen J.D.

Chief Medical OfficerDr. Fawzi Benzaghou M.D.

Scientific Co-FounderMr. John McGee Ph.D.

Chief Financial OfficerMr. Thomas Kotarakos

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
RA CAPITAL MANAGEMENT, L.P.	Director	Jun 11 '26	Buy	20.00	21,188,750	423,775,000	26,285,093	Jun 15 06:57 PM
SEBULSKY ALAN	Director	Jun 11 '26	Buy	20.00	12,500	250,000	12,500	Jun 15 05:27 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

PBLS

Parabilis Medicines Inc

Upgrade your Finviz experience